Frank Ruffo Aclaris Therapeutics, Inc. (ACRS) insider trading activity

Frank Ruffo is Chief Financial Officer of Aclaris Therapeutics, Inc.. Currently has a direct ownership of 201,883 shares of ACRS, which is worth approximately $238,221. The most recent transaction as insider was on Mar 10, 2022, when has been sold 12,823 shares (Common Stock) at a price of $15.55 per share, resulting in proceeds of $199,398. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 202K

0% 3M change

0% 12M change

Total Value Held $238,221

Frank Ruffo Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 10 2022	SELL Open market or private sale	$199,398 $15.55 p/Share	12,823 Reduced 5.97%	201,883 Common Stock
Mar 02 2022	BUY Exercise of conversion of derivative security	-	8,297 Added 3.72%	214,706 Common Stock
Mar 01 2022	BUY Exercise of conversion of derivative security	-	34,050 Added 14.16%	206,409 Common Stock
Feb 09 2022	SELL Open market or private sale	$17,572 $12.66 p/Share	1,388 Reduced 0.8%	172,359 Common Stock
Feb 01 2022	BUY Exercise of conversion of derivative security	-	3,875 Added 2.18%	173,747 Common Stock
Jun 02 2021	SELL Open market or private sale	$329,461 $21.91 p/Share	15,037 Reduced 8.13%	169,872 Common Stock
Jun 01 2021	BUY Exercise of conversion of derivative security	-	33,189 Added 15.22%	184,909 Common Stock
Apr 26 2021	SELL Open market or private sale	$714,095 $26.12 p/Share	27,339 Reduced 15.27%	151,720 Common Stock
Apr 23 2021	SELL Open market or private sale	$809,700 $26.99 p/Share	30,000 Reduced 14.35%	179,059 Common Stock
Apr 22 2021	SELL Open market or private sale	$805,200 $26.84 p/Share	30,000 Reduced 12.55%	209,059 Common Stock
Mar 02 2021	SELL Payment of exercise price or tax liability	$66,123 $23.25 p/Share	2,844 Reduced 1.18%	239,059 Common Stock
Mar 02 2021	BUY Exercise of conversion of derivative security	-	8,297 Added 3.32%	241,903 Common Stock
Mar 01 2021	SELL Payment of exercise price or tax liability	$176,432 $24.06 p/Share	7,333 Reduced 3.04%	233,606 Common Stock
Mar 01 2021	BUY Exercise of conversion of derivative security	-	25,750 Added 9.66%	240,939 Common Stock
Feb 01 2021	SELL Payment of exercise price or tax liability	$27,926 $21.35 p/Share	1,308 Reduced 0.6%	215,189 Common Stock
Feb 01 2021	BUY Exercise of conversion of derivative security	-	3,875 Added 1.76%	216,497 Common Stock
Dec 15 2020	SELL Payment of exercise price or tax liability	$1,698 $4.59 p/Share	370 Reduced 0.17%	212,622 Common Stock
Dec 15 2020	BUY Exercise of conversion of derivative security	-	1,300 Added 0.61%	212,992 Common Stock

Frank Ruffo

Chief Financial Officer

Wayne, PA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACRS shares.

Notify only if

Value

Insider Trading

Get notified when an Aclaris Therapeutics, Inc. insider buys or sells ACRS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Aclaris Therapeutics, Inc.

Track Activities on ACRS

Account